Feasibility of establishing PVC in the Ugandan health system By Juliet & Martin September 2004.

Slides:

Advertisements

Similar presentations

National Reporting & Learning System (NRLS) Reporting systems are vital in providing a core of sound, representative information on which to base analysis.

Advertisements

Module 6 Rotavirus vaccine AEFI monitoring

Safe Surgery Dr. Mohamed Selima. The problem: Complications of surgical care have become a major cause of death and disability worldwide. Data from 56.

Determining the Significant Aspects

Improving diagnosis TB laboratory strengthening.

An Introduction to Patient Safety

Sevene E, Mariano A, Mola D Faculty of Medicine / Ministry of Health Pretoria, September 2004 PHARMACOVIGILANCE SYSTEM - MOZAMBIQUE INTRODUCING PV INTO.

Walsall Healthcare NHS Trust Medicines Management.

Significant Event Audit A Guide To Starting, Sustaining & Maintaining.

1 Proposed Pharmacovigilance Plan for H5N1 Influenza Virus Vaccine Patrick Caubel, MD, PhD Head of Pharmacovigilance North America February 27, 2007.

COUNTRY ACTION PLAN for INTRODUCING AND IMPLEMENTING A PHARMACOVIGILANCE PROGRAMME IN KENYA Dorine Kagai and Wilfred Oguta Pretoria,2004.

Nigeria Dr Uzono Levi and Pharm Adegboyega Adewumi 10 th September 2004 Discussions on Country Plans Presented at the WHO Training Course on Introduction.

Capturing and Reporting Adverse Events in Clinical Research

S TRESS IN THE N EWSROOM AND F IELD.

Safety and Health Programs

Safety and Vigilance (SAV)

Safety and Health Programs

Zambia Pharmacovigilance Action Plan National Plan Revision Proposal Dr Albert Mwango Mrs Bernice MwaleSeptember 2004.

Chronic HIV Care with ART. CHALLENGES TO SELF-MANAGEMENT AND QUALITY CHRONIC CARE The acute care paradigm -Reactive care -Patient who is in office now.

Basic Pharmacovigilance Training

Importance of Documentation Demonstratin g Due Diligence concept application defense.

Entrenching the KNH Formulary to Clinical Practice DR WK SIGILAI MTC CHAIR.

Incident Report By miss.EMAN Objectives At the end of this lecture student will be able : Define incident report List elements of incident report Discuss.

 Pharmacovigilance – Patient’s standpoint Steve Arlington May 2007.

Pan American Health Organization.. Protecting the Health of Health Care Workers: Experience from the Americas Marie-Claude Lavoie Decision Making for Using.

Project co-financed by European Union Project co- financed by Asean European Committee for Standardization Implementing Agency 1 Module 13 GMP Workshop.

INFLUENCE OF MEANINGFUL USE AMONG HEALTHCARE PROVIDERS Neely Duffey, Olivia Mire, Mallory Murphy, and Dana Sizemore.

Unit #4 Establishing Committee Expectations – Safety & Health Programs 1.

1 MÉNARD, MARTIN, AVOCATS THE RIGHT TO SAFE CARE LEGAL ISSUES By: Mtre. Jean-Pierre Ménard, Ad. E.

Policy #C: CHAP CII.7I  To define the reporting, follow-up, and feedback process for incidents involving patients and Ambercare personnel.

Safety and Health Programs 1. Benefits of Effective Safety and Health Programs Reduce work related injuries and illnesses Improve morale and productivity.

Practice Management: Tips for a Successful GI Practice James J. Weber, MD President & CEO of Texas Digestive Disease Consultants.

Collecting data in clinic.  Aim of BADBIR  Definition of Adverse Events  Adverse events in BADBIR  Adverse event recording in hospital case notes.

OSHAX.org - The Unofficial Guide To the OSHA1. Benefits of Effective Safety and Health Programs Reduce work related injuries and illnesses Improve morale.

Preventing Surgical Complications Prevent Harm from High Alert Medication- Anticoagulants in Primary Care Insert Date here Presenter:

PHARMACOVIGILANCE AND CLINICAL TRIALS DIVISION 20 August 2015 Victoria Falls Protecting Your Right to Quality Medicines and Medical Devices.

Reporting of Adverse Drug Reactions: a study among Clinicians

Topic 6 Understanding and managing clinical risk.

Some Perspectives on a Draft Pharmacovigilance Protocol-reference to HIV/AIDS I Ralph Edwards.

Chapter 6 CRISIS MANAGEMENT. Introduction - Crisis: ◦is a situation that specifically involves a pharmaceutical product, medical device or activity with.

Risk Management & Clinical Research Duke University Health System Orientation 2008 Clinical Research Coordinators Douglas Borg, MHA, ARM, CPHRM, DFASHRM.

Prime Responsibility for Radiation Safety

Social Pharmacy Lecture no. 6 Rational use of drugs Dr. Padma GM Rao

METHODS TO STUDY DRUG SAFETY PROBLEMS animal experiments clinical trials epidemiological methods –spontaneous reporting case reports case series –Post-Marketing.

Summary of Findings Improving the System of Reporting and Interpreting Unexpected Serious Adverse Events to Investigators Conducting Research Under an.

Smallpox Vaccine Safety and Reporting Adverse Events Department of Health and Human Services Centers for Disease Control and Prevention December 2002.

Promoting Rational Use of ARVs in HIV/AIDS Clinics in Tanzania Presented by Salama Mwakisu -MSH.

Training course on the Pharmacovigilance of antiretroviral medicines 23 – 28 November 2009 Rationale, Objectives and Expected Outcomes.

RML Specialty Hospital FALL PREVENTION PROGRAM NATIONAL NALTH WINNER 2006 for BEST PRACTICE.

Downloaded from Partnership for Implementation of workplace Programs Emmanuel Alhassan NACA ICASA, Abuja,

Dr Mary Couper Quality Assurance and Safety of Medicines WHO

Ebola preparedness and Response in Lao PDR. Outline Objective The preparedness contingency plan Phase 1: Preparedness Phase 2: Contingency for response.

PHARMACOVIGILANCE PLAN FOR TANZANIA PREPARED BY EMMA & MARY 10 TH SEPTEMBER 2004.

Terry McInnis, MD MPH President- Blue Thorn, Inc - Mobile Co-Chair- Center for.

Core Topic 11 Documentation, record keeping and reporting.

System Analysis of Clinical Incidents The London Protocol

IIPP An Overview of the Injury and Illness Prevention Program.

1 Pharmacovigilance & the New National Adverse Drug Reaction (ADR) Reporting System Michael Bonett, Quality Assessor Post-Licensing Directorate Medicines.

10 Risk Management.

8. Causality assessment:

3. Key definitions Multi-partner training package on active TB drug safety monitoring and management (aDSM) July 2016.

Pharmacovigilance in clinical trials

9. Introduction to signal detection

Pharmacovigilance in Uganda

68.3 million errors (28% of total) cause moderate or serious harm

7. aDSM slides - Indicators of aDSM implementation and programme management Multi-partner training package on active TB drug safety monitoring and management.

مدیریت عدم انطباق Nonconformity Management

11 iii. Define management and supervision roles and responsibilities

Presentation transcript:

Feasibility of establishing PVC in the Ugandan health system By Juliet & Martin September 2004

Why monitor drugs To document unknown Adverse Drug Reactions (ADR) and maximize safety To encourage health professionals to share concerns about drugs – create an awareness of safety issues & drugs

What should be monitored? All drugs, but priority to be given to ARVs, anti malarials, TB drugs.

Which reports to be investigated? All suspected ADR but with special emphasis on unexpected ADRs and those that significantly affect compliance

Who monitors? Health workers and care givers The PV teams and MTC

How should monitoring occur? patients NPVC HW RPVC monitoring Monitoring monitoring Regular reports Less regular

When to encourage reporting events or reactions 2 weeks to one month

How to manage non serious events Sensitization of patients and health workers on frequent occurrences that may affect compliance

Resources available HR can be mobilized Financial resources are limited and needs mobilizing

Critical success factors Adequate financial resources Good communication A good infrastructure (labs, equipment etc) Well trained and sensitized health workers Good will by all parties